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ABSTRACT
Intralobar pulmonary sequestration is an uncommon congenital lung anomaly which consists of a mass of normal lung tissue not connected 
to the normal tracheobronchial tree and supplied by an anomalous systemic artery. Carbohydrate antigen 19-9 (CA 19-9) is widely accepted 
as a tumour marker for biliary, pancreatic and gastrointestinal cancer. However, CA 19-9 may also be increased in patients with benign 
disease. We describe the case of a 56-year-old woman with intralobar pulmonary sequestration who underwent unnecessary and extensive 
diagnostic abdominal examinations because of an increase in CA 19-9 serum levels. 
LEARNING POINTS
• Knowledge of pulmonary sequestration causing increased serum CA 19-9 is important for the internist because it can help in the 
differential diagnosis even with neoplastic disease.
• Such awareness can also decrease the use of antibiotics.
• Familiarity with the condition can reduce the number of invasive examinations performed to exclude neoplasms of the gastrointestinal 
tract.
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INTRODUCTION
Pulmonary sequestration (PS) is a rare congenital abnormality characterized by the presence of non-functioning lung tissue lacking 
communication with normal bronchial trees and supplied by an anomalous systemic artery instead of a pulmonary arterial branch[1,2]. There 
are two forms of PS: intralobar and extralobar. Both probably develop from an accessory lung bud in the primitive foregut. In the intralobar 
form, the sequestered section of the lung lies within the normal pulmonary visceral pleura, while in extralobar sequestration, the pulmonary 
tissue is separated from normal lung, is surrounded by its own pleura, and can also be extrathoracic[3,4]. 
Since it is an anatomical condition, PS is usually associated with pulmonary infection, which is the most common clinical feature, although 
non-specific symptoms may also be present. PS may occasionally be misdiagnosed as a pulmonary abscess or tumour and only correctly 
identified after surgery[4].
Carbohydrate 19-9 antigen (CA 19-9) is a glycoprotein mainly expressed on the cell surfaces of biliary and pancreatic duct cells. High CA 
19-9 levels are considered strongly suggestive of malignancy of the pancreas, biliary system or gastrointestinal tract. However, slight 
increases in this marker (usually not more than four to five times the normal limit) are reported in several non-malignant diseases such as 
chronic hepatitis, primary biliary cirrhosis[5,6] and primary sclerosing cholangitis[7]. An increase in CA 19-9 has been rarely reported in some 
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cases of PS[2,3].
We describe the case of a patient with recurrent pulmonary infections associated with an elevated serum CA 19-9 level, who underwent 
extensive gastrointestinal diagnostic evaluation before intralobar PS was identified.
CASE REPORT
A 56-year-old woman was admitted to Gemelli Hospital with asthenia and a 6-month history of fever and cough. Since symptoms persisted 
after antibiotic therapy (ciprofloxacin and clarithromycin) together with steroids (oral prednisone 25 mg daily for 2 weeks, with subsequent 
tapering over 3 weeks), a CT scan of the chest was performed 3 months later and showed multiple parenchymal consolidations in the basal 
lobe of the left lung and shaded ‘ground glass’ areas. The pneumologist therefore suggested another course of antibiotics (piperacillin/
tazobactam and trimethoprim). Since a lung neoplasm was suspected, the patient’s general practitioner also ordered tests for tumour 
serological markers which showed increased CA 19-9. Consequently, to exclude an abdominal malignancy, the patient underwent 
gastroscopy, colonoscopy, a US scan and a CT scan, none of which revealed significant abnormalities. 
A week after discontinuation of antibiotic therapy, the patient complained of a recurrence of fever and cough without sputum and attended 
our emergency room. 
At admission in our department she was in good general condition with no pulmonary or digestive symptoms. No fever or other specific 
abnormalities were reported. The patient was a biologist, an ex-smoker and had no family history of pulmonary tuberculosis or bronchiectasis. 
Physical examination revealed only a minimal decrease in vesicular sounds in the left lower lung field. 
Blood tests showed an increase in inflammatory markers (C-reactive protein 60.3 mg/l, fibrinogen 647 mg/dl), while procalcitonin was 
normal and beta-D-glucan was negative. Increased serum CA 19-9 levels were confirmed (240 IU/ml). 
The CT scan showed a parenchymal consolidation with necrotic-like phenomena in the left lower lobe with inadequate recognition of sub-
segmental bronchial structures. The presence of an aberrant artery arising from the superior border of the aorta was suspected (Fig. 1).
In order to identify the aetiology of the infection, bronchoscopy with bronco-alveolar lavage (BAL) was performed. Endoscopic examination 
was negative as were microbiological tests (BAL and blood culture, Legionella urinary antigen test, pneumococcal urinary antigen test, 
Staphylococcus aureus nasal swab, throat swab, Quantiferon test, and serology for Mycoplasma pneumoniae, Chlamydia pneumoniae, and 
influenza A and B virus). The antistreptolysin O titre was normal.
Intravenous antibiotic therapy with meropenem 1 g three times a day and clindamycin 900 mg three times a day was administered for 10 
days during hospitalization and continued at home with oral clindamycin 300 mg times a day and cefditoren 400 mg twice a day. Because 
fever episodes and cough persisted over the following 2 weeks, the patient was readmitted and underwent surgery.
Surgery confirmed the presence of an arterial vessel from the abdominal aorta that supplied the left lower lung (Fig. 2). Histological 
examination of the resected tissue revealed chronic mucopurulent inflammation of the bronchial mucosa and lung tissue, as well as 
microabscess formation in the focal area, all findings which were consistent with PS. After pulmonary resection, fever, inflammatory blood 
markers and serum CA 19 9 levels (Fig. 3) rapidly decreased to normal ranges.
The patient is well 6 months after surgery with no recurrence of symptoms.
Figure 1. Chest CT showing a heterogeneous low density mass located in the left lower 
lobe (red arrows) and an aberrant artery (black arrow)
Figure 2. Left lower lobe: dilated bronchioles with a thickened wall (blue arrow) and 
small cavities and multiple abscesses containing necrotic debris, stagnant blood or 
fluid (yellow arrow)
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DISCUSSION
To best of our knowledge, this is the first report from Italy of PS associated with an increase in CA 19-9. PS is a rare lung congenital 
malformation where the absence of a connection with the normal bronchial tree favours infection and can be a cause of recurrent 
pneumonia. The most common clinical features are fever and cough due to various bacteria and occasionally uncommon pathogens such as 
Mycobacterium tuberculosis and fungus[1–4].
The presence of high levels of CA 19-9 is usually considered to strongly suggest malignant pancreatic-biliary or gastrointestinal disease, but 
this serum marker may also increase in a number of non-malignant diseases[5]. In patients with PS, an increase in serum CA 19.9 has been 
reported anecdotally[3–6]. Only a few cases of elevated CA 19-9 serum values in association with PS have been reported to date[6]. 
Clinicians are not generally aware of the relationship between elevated CA 19.9 levels and PS because the condition is rare and also likely 
underestimated. Indeed, when recurrent pneumonia is seen in clinical practice, CA 19-9 tests are not requested by physicians if symptoms 
of malignancy are absent. Furthermore, when an increase in CA 19-9 has been reported in patients with PS, as in our case, no abdominal 
symptoms are found and in most cases it is an occasional finding[2,3]. 
CA 19-9 is synthesized by normal bronchial epithelial cells, and is elevated in blood during epithelial cell proliferation and accumulation in 
PS tissue. Other reports indicate that proliferation of bronchial epithelial cells causes CA 19-9 elevation via a chronic inflammatory process 
due to infection by pathogenic organisms such as Aspergillus or Mycobacterium. 
Our case report highlights two points. The anatomic lung anomaly was not promptly found at the first outpatient CT scan although post-
diagnostic review of images showed radiological features suggestive of PS were already present. Therefore, in patients with a history of 
recurrent pulmonary infection, PS should be considered a cause of poor image resolution, even though it is a rare pathological condition. 
Second, we underline the difficulty in identifying the cause of an increase in CA 19-9 when PS is not recognized. In such cases patients may 
undergo a large number of unnecessary diagnostic examinations. 
In conclusion, our case confirms the association between PS and increased CA 19-9 levels. Consequently, in patients with PS and elevated 
CA 19-9, an extensive diagnostic process aimed at excluding abdominal malignancy is not necessary. Further basic studies regarding the 
mechanism of CA 19-9 increase in PS are required.
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Figure 3. Serum carbohydrate antigen 19-9 (CA19-9) levels before and after surgery 
for intralobar pulmonary sequestration
